Compugen

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses on research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Compugen reports Q1 loss, showcases promising cancer immunotherapy approach

Compugen's Q1 2023 performance reflects a strategic focus on capital efficiency and milestone achievement.
Their innovative triple combination approach in cancer immunotherapy shows promise, with encouraging clinical benefits observed.
While managing R&D expenses and translating clinical benefits into marketable products are challenges, opportunities exist in disciplined cash deployment and exploration of biomarkers.
Overall, Compugen's financial discipline, promising clinical data, and strategic focus position them well for future growth in the oncology space.

Compugen (CGEN) reports positive ASCO results and solid financial standing

Compugen (CGEN) showcases promising results in cancer immunotherapy combinations, maintaining a strong financial position despite increased R&D expenses. The company's differentiated approach and focus on milestone achievement through 2024 position it well for future growth, although challenges in enrollment delays and managing expenses persist.

Compugen reports Q3 progress with promising clinical data and partnerships

Compugen's Q3 2023 performance reflects progress in clinical trials and financial stability with a cash balance of $57.5 million.
Strengths lie in innovative drug discovery approaches, successful clinical outcomes, and strategic partnerships.
Challenges include competitive enrollment landscape, cost management, and market acceptance of novel treatments.
Opportunities exist in upcoming data reporting, novel drug targets, and collaborations for future growth and success.

Compugen reports robust earnings and strategic partnerships drive growth

Compugen's Q4 2023 performance reflects strong financial results and notable achievements in clinical advancements and partnerships.
The company's financial stability, strategic focus, and robust pipeline position them well for future growth and innovation.
While facing challenges in clinical trial outcomes and partnership strategies, Compugen has opportunities to drive further growth through data insights and collaborations.

Compugen reports solid Q1 performance, poised for growth in 2024

Compugen's Q1 2024 performance reflects financial stability, operational efficiency, and progress in advancing key drug candidates towards clinical trials, underpinned by a robust AI discovery platform and strategic partnerships.
While challenges like ongoing R&D investments and achieving profitability persist, opportunities in milestone achievements, data readouts, and strategic collaborations position Compugen for future growth and value creation.
Navigating the biopharmaceutical landscape with innovation, financial discipline, and strategic foresight, Compugen stands poised to capitalize on market opportunities, drive pipeline progression, and enhance shareholder value.

Compugen reports Q2 revenue of $6.7M, highlights innovative drug strategies

Compugen's Q2 2024 performance reflects steady revenue generation and prudent financial management. The company's strengths in innovative drug development and strategic collaborations present promising growth opportunities. Addressing challenges in clinical evidence and cash burn will be crucial for sustained success.

Compugen reports solid Q3 earnings, advances promising ovarian cancer therapies

Compugen's strong financial position, promising clinical data on multiple therapies, and strategic focus on ovarian cancer treatment advancements position the company for potential growth. Challenges lie in maintaining treatment efficacy and navigating regulatory discussions for future developments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AppHarvest

Bitfarms Ltd

Globalstar

Guardforce AI Co Ltd

Today we look at five penny stocks to buy according to some of Wall Street's analyst firms. The post 5 Best Penny Stocks Under $5 To Buy According To Analysts Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Best Penny Stocks Under $5 To Buy According To Analysts Right Now

Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q4 2021 Results - Earnings Call Transcript

HOLON, Israel , Feb. 24, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), ("Compugen", the "Company"), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today the appointment of Mathias Hukkelhoven, Ph.D.

Compugen Announces Appointment of Dr. Mathias Hukkelhoven to its Board of Directors

HOLON, Israel, Feb. 24, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), ("Compugen", the "Company"), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today reported financial results for the fourth quarter ended December 31, 2021, and full year 2021 and provided an update on recent Company highlights.

Compugen Reports Fourth Quarter and Full Year 2021 Results

HOLON, Israel, Feb. 10, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its fourth quarter and full year 2021 financial results on Thursday, February 24, 2022, before the U.S. financial markets open.

Compugen to Release Fourth Quarter and Full Year 2021 Results on Thursday, February 24, 2022

Archer Aviation

Joby Aviation

Nano Dimension

Quantum-Si

Skillz

Surface Oncology Inc

Cathie Wood stocks to watch right now. The post 7 Penny Stocks To Buy Based On Cathie Wood's ARK Invest Holdings appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

7 Penny Stocks To Buy Based On Cathie Wood's ARK Invest Holdings

HOLON, Israel, Feb. 9, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that management will present at the 11th Annual SVB Leerink Global Healthcare Conference (virtual), on Wednesday, February 16, 2022 at 12:00 pm ET.

Compugen to Present at the 11th Annual SVB Leerink Global Healthcare Conference

HOLON, Israel, Jan. 18, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ-GM: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the United States Patent and Trademark Office (USPTO) has granted Compugen a new patent covering method of use for COM701, Compugen's potential first-in-class therapeutic antibody targeting PVRIG, or back-up anti-PVRIG antibody, in triple combination with any anti-PD-1 and any anti-TIGIT antibody for the treatment of cancer.

Compugen Expands COM701 Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use with anti-PD-1 and anti-TIGIT Antibodies

HOLON, Israel, Dec. 9, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the presentation of preliminary translational data from patient biopsies demonstrating immune activation in the tumor microenvironment (TME) after treatment with COM701, Compugen's potentially first-in-class anti-PVRIG antibody, as a monotherapy and in combination with nivolumab at the TIGIT Therapies Digital Summit.

Compugen Presents Preliminary Translational Data Demonstrating Immune Activation in the Tumor Microenvironment by COM701 at the TIGIT Therapies Digital Summit

AquaBounty Technologies

3 penny stocks attracting attention from ARK Invest family of funds. The post 3 Penny Stocks Cathie Wood's ARK Invest Bought In 2021, Will You?

3 Penny Stocks Cathie Wood's ARK Invest Bought In 2021, Will You?

Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q3 2021 Results - Earnings Call Transcript

Compugen (CGEN) announces an expansion of its collaboration agreement with Bristol Myers Squibb and a $20 million equity investment by the latter.

Compugen (CGEN) Stock Up on Bristol Myers' $20M Investment

- COM701, Opdivo® and BMS-986207, triple combination dose escalation Phase 1/2 data being presented at 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) clears the path to studies in select biomarker informed tumor types - COM902 monotherapy dose escalation Phase 1 data being presented at SITC shows favorable safety profile, Phase 1 cohort expansion in combination with COM701 currently enrolling - COM701 translational data being presented at SITC support the differentiation of PVRIG compared to TIGIT and PD-1 as a novel checkpoint in the DNAM axis - Strong cash position with $20 million equity investment from Bristol Myers Squibb and $6 million milestone payment from AstraZeneca HOLON, Israel, Nov. 12, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for the third quarter ended September 30, 2021.

Compugen Reports Third Quarter 2021 Results

HOLON, Israel, Nov. 12, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the presentation of new translational preliminary data detailing the differentiated profile of PVRIG compared to TIGIT and PD-1 as a novel checkpoint in the DNAM axis, supporting its potential role as a dominant checkpoint involved in stem-like memory T cells and dendritic cell (DCs) interaction at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), being held on November 10-14, 2021.

Compugen Presents Initial Translational Data Supporting the Differentiation of PVRIG Compared to TIGIT and PD-1 as a Novel Checkpoint on the DNAM Axis at SITC 2021

HOLON, Israel, Nov. 12, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the presentation of preliminary results from its ongoing Phase 1 dose escalation study evaluating COM902, Compugen's anti-TIGIT antibody, in patients with advanced solid tumors at the 36th Annual Meeting of the Society for Immunotherapy of Cancer, being held on November 10-14, 2021.

Compugen Presents Preliminary Results from Phase 1 Dose Escalation Monotherapy Study of COM902 a High Affinity Anti-TIGIT Antibody at SITC 2021

HOLON, Israel, Nov. 12, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the presentation of preliminary results from its ongoing Phase 1/2 triple combination dose escalation study evaluating the combination of COM701, Compugen's potentially first-in-class anti-PVRIG antibody, with Bristol Myers Squibb's (NYSE: BMY) anti-PD-1, Opdivo® and BMS-986207, an investigational anti-TIGIT antibody, at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), being held November 10-14, 2021.

Compugen Presents Preliminary Results from Phase 1/2 Dose Escalation Study of COM701 with Opdivo® and BMS-986207 (Anti-TIGIT Antibody) at SITC 2021

The company is deepening its partnership with Bristol Myers Squibb.

Why Compugen Surged 14% Higher on Thursday

Bristol-Myers

Shares of Compugen Ltd. CGEN, -2.33% gained 13.4% in premarket trading on Thursday after Bristol Myers Squibb Co. BMY, -0.12% completed a $20 million investment in the company.

Compugen's stock jumps after Bristol Myers Squibb completes $20 million investment into the company

The stock price of Compugen Ltd. (NASDAQ: CGEN) increased by over 15% pre-market today.

Compugen (CGEN) Stock: Why The Price Jumped

HOLON, Israel, Nov. 11, 2021 /PRNewswire/ --  Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that Bristol Myers Squibb (NYSE: BMY) completed its $20 million investment in Compugen  in consideration for the issuance of 2,332,815 shares of Compugen purchased at $8.57333 per share, representing a 33% premium over the closing price on November 9, 2021.

Compugen Announces Collaboration Expansion with Bristol Myers Squibb alongside $20 Million Equity Investment

HOLON, Israel, Oct. 26, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its third quarter 2021 financial results on Friday, November 12, 2021, before the U.S. financial markets open.

Compugen to Release Third Quarter 2021 Results on Friday, November 12, 2021

HOLON, Israel, Oct. 4, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that Compugen is entitled to receive a $6 million milestone payment from AstraZeneca (LSE: AZN) (STO: AZN) (Nasdaq: AZN) triggered by the dosing of the first patient in a Phase 1/2 study evaluating AZD2936, a TIGIT/PD-1 bispecific antibody, in patients with advanced or metastatic non-small cell lung cancer.

Compugen Announces Milestone Payment from AstraZeneca Triggered by First Patient Dosed with TIGIT Bispecific Derived from COM902

HOLON, Israel, Oct. 1, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that new clinical and preclinical data will be presented at the 36th Annual Meeting of the Society for Immunotherapy of Cancer, which will be held on November 10-14, 2021.

Compugen To Present Clinical Data from anti-TIGIT COM902 Monotherapy and Triple Combination Dose Escalation Studies at SITC 2021

HOLON, Israel, Sept. 14, 2021 /PRNewswire/ -- Compugen Ltd.

Compugen to Present at the Cantor Global Healthcare Conference

HOLON, Israel, Aug. 26, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that management will present at the Morgan Stanley 19th Annual Global Healthcare Conference (virtual), on Thursday, September 9, 2021 at 11:00 am ET.

News for Compugen Stock (CGEN)